DekaBank Deutsche Girozentrale Takes $10.81 Million Position in Qiagen N.V. $QGEN

Key Points

• DekaBank Deutsche Girozentrale opened a new position in Qiagen during the first quarter, buying 270,000 shares valued at about $10.81 million, equal to roughly 0.13% of the company.
• Analyst sentiment on Qiagen is mixed: the stock currently carries an average “Hold” rating, with a consensus price target of $43.34 after several recent upgrades and downgrades.
• Qiagen reported quarterly EPS of $0.54, in line with expectations, and recently increased its annual dividend to $0.35 per share from $0.26.

DekaBank Deutsche Girozentrale acquired a new stake in shares of Qiagen N.V. (NYSE:QGEN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 270,000 shares of the company's stock, valued at approximately $10,811,000. DekaBank Deutsche Girozentrale owned approximately 0.13% of Qiagen as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of QGEN. United Services Automobile Association acquired a new position in Qiagen in the 1st quarter worth about $239,000. Prudential Financial Inc. boosted its stake in shares of Qiagen by 74.9% during the second quarter. Prudential Financial Inc. now owns 8,873 shares of the company's stock valued at $426,000 after purchasing an additional 3,799 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Qiagen by 123.7% during the second quarter. Invesco Ltd. now owns 1,006,025 shares of the company's stock worth $48,350,000 after purchasing an additional 556,387 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Qiagen by 226.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company's stock worth $125,000 after purchasing an additional 1,802 shares during the last quarter. Finally, First Trust Advisors LP bought a new stake in shares of Qiagen during the second quarter worth about $3,639,000. Institutional investors and hedge funds own 70.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on QGEN shares. Robert W. Baird set a $43.00 price objective on shares of Qiagen and gave the company an "outperform" rating in a report on Wednesday, April 29th. Weiss Ratings lowered shares of Qiagen from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, May 29th. Barclays set a $38.00 price target on shares of Qiagen and gave the company an "equal weight" rating in a research report on Wednesday, April 29th. Wall Street Zen downgraded shares of Qiagen from a "buy" rating to a "hold" rating in a research note on Saturday, March 28th. Finally, Morgan Stanley raised shares of Qiagen from an "overweight" rating to an "overweight" rating and raised their price target for the company from $40.00 to $42.00 in a research note on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Qiagen currently has an average rating of "Hold" and a consensus price target of $43.34.

Qiagen Trading Up 0.1%

NYSE QGEN opened at $41.19 on Monday. The firm has a market capitalization of $8.49 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 4.11 and a beta of 0.64. The business's 50-day moving average price is $37.34 and its two-hundred day moving average price is $42.33. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. Qiagen N.V. has a 12 month low of $32.53 and a 12 month high of $57.81.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.54. The company had revenue of $492.32 million during the quarter, compared to the consensus estimate of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same period last year, the company earned $0.56 earnings per share. On average, analysts expect that Qiagen N.V. will post 2.43 EPS for the current year.

Qiagen Increases Dividend

The company also recently declared an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were issued a dividend of $0.35 per share. This represents a yield of 90.0%. The ex-dividend date was Tuesday, July 7th. This is a positive change from Qiagen's previous annual dividend of $0.26. Qiagen's dividend payout ratio (DPR) is 18.32%.

Qiagen Profile

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.